1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Medacta Group SA

Medacta Group SA

129.40
EUR
+3.60
(+2.86%)
3.34BMarket Cap
Mar 12Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
10.95
12.23
13.63
15.53
15.12
18.16
21.88
25.6
29.65
34.32
- -
Basic EPS, GAAP
- -
1.96
1.67
2.29
0.59
1.85
2.58
2.32
2.37
3.66
4.79
- -
Free Cash Flow per Basic Share
- -
1.4
0.57
0.56
-0.45
1.11
-0.03
0.11
-0.36
0.12
0.48
- -
Dividend per Share
- -
- -
3.14
3.26
- -
- -
- -
0.52
0.55
0.56
0.74
- -
Book Value per Share
5.43
7.34
5.08
4.45
6.16
8.24
11.33
13.76
16.56
19.06
22.93
22.93
Tangible Book Value per Share
4.99
6.67
3.49
2.45
3.88
5.8
8.73
11.25
13.98
16.37
19.84
19.84
Basic Weighted Avg Shares
20
20
20
20
20
20
20
20
20
20
20
20
Sales/Revenue/Turnover
- -
219
245
273
311
302
363
437
511
591
684
- -
Operating Margin (%)
- -
23.18
20.72
22.82
8.57
16.35
16.19
14.06
14.57
15.38
16.29
- -
Depreciation Expense
- -
19
22
25
34
37
40
51
58
65
74
- -
Net Income, GAAP
- -
39
33
46
12
37
52
46
47
73
95
- -
Effective Tax Rate (%)
- -
19.33
29.26
21.17
13.01
7.11
7.09
15.59
19.35
16.96
17.2
- -
Profit Margin (%)
- -
17.9
13.69
16.78
3.82
12.26
14.19
10.58
9.27
12.34
13.96
- -
Working Capital
42
69
47
61
67
73
91
195
199
238
233
233
LT Debt
14
20
56
113
100
79
63
157
147
182
157
157
Total Equity
109
147
102
89
123
165
226
275
330
380
457
457
Return on Invested Capital (%)
- -
22.94
17.61
20.29
5.99
14.48
15.6
12.73
12.16
13.01
15.43
- -
Return on Capital (%)
- -
23.78
17.91
21.01
5.61
13.53
16.24
12.27
10.82
13.73
15.11
- -
Return on Common Equity (%)
- -
30.71
26.95
47.97
11.17
25.76
26.35
18.46
15.66
20.54
22.83
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
59
12
103
LT Borrowings
143
- -
114
LT Finance Leases
39
39
44
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
- -
- -
3,341

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
395
442
450
Cash, Cash Equivalents & STI
32
41
33
Accounts Receivable, Net
108
118
121
Inventories
234
267
271
Total Current Liabilities
158
185
217
Payables & Accruals
- -
- -
- -
ST Debt
59
12
103
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.84%
22.85%
20.26%
Free Cash Flow
- -
-173.32%
289.64%
Net Income, GAAP
- -
23.19%
30.97%
Sales/Revenue/Turnover
- -
17.74%
15.79%
Total Cash Common Dividend
- -
- -
30.97%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
511
2024
- -
- -
591
2025
- -
- -
684

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.37
2024
- -
- -
3.66
2025
- -
- -
4.79

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.55
2024
- -
- -
0.56
2025
- -
- -
0.74

Company Description

Company Profile APIChatGPT
CEO
Francesco Siccardi
Full Time Employees
2,165
Sector
Health technology
Industry
Medical specialties
Address
Strada Regina, 34 Castel San Pietro TI Switzerland 6874
IPO Date
Apr 4, 2019
Website
medacta.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Medacta Group S.A. Medacta Group SA develops, manufactures and distributes orthopedic and neurosurgical medical devices worldwide. The company offers a comprehensive portfolio of implants and enabling technologies for hip and knee arthroplasty including the MPACT 3D METAL MONOCER femoral system, AMIS hip stems, QUADRA knee systems and cementless solutions such as VERSAFIT cup and MASTERLOC; revision systems like M-VIZION and SENSITIN DM converter; sports medicine products covering shoulder, knee, hip and foot & ankle procedures; spine solutions encompassing Mecta-C cervical implants, M.U.S.T. pedicle screws, MectaLIF interbody devices and personalized technologies like MySpine and NEXTAR Spine augmented reality platform; as well as advanced materials including HIGHCROSS polyethylene and MECTAGRIP surfaces, personalized patient-matched implants via MySolutions ecosystem, and instrumentation such as GASTON minimally invasive tools. Medacta operates in over 60 countries across Europe, North America, Asia Pacific, EMEA and Latin America, targeting surgeons, hospitals and ambulatory surgical centers with a focus on minimally invasive and patient-specific solutions. Founded in 1999 by orthopedic patient Dr. Alberto Siccardi and headquartered in Castel San Pietro, Switzerland, the company recently acquired Parcus Medical in March 2025 to accelerate expansion in sports medicine, integrating its shoulder and arthroscopy portfolio, US manufacturing site in Sarasota, Florida for vertical integration, and distributor network in over 45 countries while enhancing presence in the fast-growing US ASC market; it also reported strong H1 2025 revenue growth of 19.8% in constant currency across all regions and business lines, upgrading full-year guidance to 16-18% growth and 28% adjusted EBITDA margin.